Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alaunos Therapeutics Inc (Alaunos Therapeutics) is a clinical stage cellular immuno-oncology company that focuses on developing innovative T-cell therapies for cancer treatment. Its activities carry out the research and development of non-viral T-cell therapy platforms, specifically targeting neoantigens through TCR-T cell therapies. Alaunos Therapeutics products include the Sleeping Beauty transposon/transposase system and the hunTR platform, that are used to genetically modify T-cell receptors to target cancer-specific mutations. The company's products are utilized by healthcare providers and researchers in the oncology sector to treat solid tumors. Alaunos Therapeutics is headquartered in Houston, Texas, the US.
Headquarters
United States of America
Address
501 E Las Olas Blvd, Suite 300, Fort Lauderdale, Florida, 33301
Website
alaunos.com
No of Employees
1
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TCRT (NASD)
Revenue (2024)
$5,000
-50%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
10.8%
(2024 vs 2023)
Market Cap*
$6.3M
Net Profit Margin (2024)
XYZ
-78.5%
(2024 vs 2023)
* As of and is in US$
Alaunos Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline Product: | Development and Commercialization of In-Licensed Cancer Drugs | hunTR |
| Library TCR- T Cell Therapy: Lung, Colon, Endometrium, Pancreas, Ovary, Bile Duct | T-Cell Therapy | |
| mbiL TCR- T Cell Therapy: Solid Tumors |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Stake Sale | In May, the company sold its 5.09% stake to PMGC Capital LLC, an investment firm. |
| 2022 | Corporate Changes/Expansions | In January, the company changed its name to Alaunos Therapeutics Inc. |
| 2020 | Contracts/Agreements | In June, the company signed an agreement with Aldevron, to produce plasmid DNA for T cell therapy of solid tumors. |
Competitor Comparison
| Key Parameters | Alaunos Therapeutics Inc | Iovance Biotherapeutics Inc | Poseida Therapeutics Inc | Crown Bioscience Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Fort Lauderdale | San Carlos | San Diego | San Diego |
| State/Province | Florida | California | California | California |
| No. of Employees | 1 | 975 | 350 | - |
| Entity Type | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Holger Weis | Chief Executive Officer; Chairman | Executive Board | 2025 | 62 |
| Ferdinand Groenewald | Secretary; Vice President - Finance | Senior Management | 2024 | 40 |
| Michael A. Jerman | Director | Non Executive Board | 2025 | - |
| Jaime Vieser | Director | Non Executive Board | 2020 | 55 |
| Robert W. Postma | Director | Non Executive Board | 2021 | 71 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer